ATE448312T1 - Leitsequenzen zur verwendung bei der produktion von proteinen - Google Patents

Leitsequenzen zur verwendung bei der produktion von proteinen

Info

Publication number
ATE448312T1
ATE448312T1 AT04787205T AT04787205T ATE448312T1 AT E448312 T1 ATE448312 T1 AT E448312T1 AT 04787205 T AT04787205 T AT 04787205T AT 04787205 T AT04787205 T AT 04787205T AT E448312 T1 ATE448312 T1 AT E448312T1
Authority
AT
Austria
Prior art keywords
proteins
production
dna constructs
leader sequences
guide sequences
Prior art date
Application number
AT04787205T
Other languages
English (en)
Inventor
Philippe Dupraz
Michel Kobr
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE448312T1 publication Critical patent/ATE448312T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04787205T 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen ATE448312T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103580 2003-09-26
US50693903P 2003-09-29 2003-09-29
PCT/EP2004/052302 WO2005030963A1 (en) 2003-09-26 2004-09-24 Leader sequences for use in production of proteins

Publications (1)

Publication Number Publication Date
ATE448312T1 true ATE448312T1 (de) 2009-11-15

Family

ID=34924107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787205T ATE448312T1 (de) 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen

Country Status (8)

Country Link
US (1) US20070141666A1 (de)
EP (1) EP1670918B1 (de)
JP (1) JP4809227B2 (de)
AT (1) ATE448312T1 (de)
AU (1) AU2004276522B2 (de)
CA (1) CA2537340A1 (de)
ES (1) ES2333724T3 (de)
WO (1) WO2005030963A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042121A1 (en) * 1998-02-20 1999-08-26 University Of Miami Modified heat shock protein-antigenic peptide complex
JP4467815B2 (ja) * 2001-02-26 2010-05-26 富士通マイクロエレクトロニクス株式会社 不揮発性半導体メモリの読み出し動作方法および不揮発性半導体メモリ
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
JP2011515399A (ja) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ 熱ショックタンパクｇｐ９６ワクチン接種及びそれを用いた方法
AU2009316371B2 (en) * 2008-11-21 2014-02-20 University Of Miami HIV/SIV vaccines for the generation of mucosal and systemic immunity
PL2968470T3 (pl) 2013-03-12 2021-05-31 The General Hospital Corporation Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób
WO2015041718A1 (en) 2013-09-20 2015-03-26 The General Hospital Corporation Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11518793B2 (en) 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3983537A1 (de) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2-zusammensetzungen und verfahren zur abstimmbaren regulierung
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AR124599A1 (es) 2021-01-08 2023-04-12 Strand Therapeutics Inc Constructos de expresión y usos de estos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
CZ203898A3 (cs) 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
CA2325022A1 (en) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
AU781460B2 (en) 1999-02-12 2005-05-26 Amgen, Inc. Glycosylated leptin compositions and related methods
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies

Also Published As

Publication number Publication date
WO2005030963A1 (en) 2005-04-07
JP4809227B2 (ja) 2011-11-09
ES2333724T3 (es) 2010-02-26
US20070141666A1 (en) 2007-06-21
EP1670918B1 (de) 2009-11-11
JP2007506420A (ja) 2007-03-22
CA2537340A1 (en) 2005-04-07
AU2004276522B2 (en) 2010-12-02
EP1670918A1 (de) 2006-06-21
AU2004276522A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
ATE541931T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE457355T1 (de) Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE60137829D1 (de) Menschliche stra6 polypeptide
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
CY1110546T1 (el) Μεθοδοι για παραγωγη μεγαλης κλιμακας πεδιου kringle 2 συν πρωτεαση σερινης (k2s) του πλασμινογονου σε προκαρυωτες
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE374825T1 (de) Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
PT1366161E (pt) Anticorpo anatagonista anti-pro842
NO20061858L (no) Ledersekvenser for anvendelse ved produksjon av proteiner
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.
ATE386129T1 (de) Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
DE69937756D1 (de) Menschliches Prostasin-ähnliches Protein und dafür kodierende Nukleinsäure
DE69939227D1 (de) Menschliches A33-Antigen-ähnliches Protein und dafür kodierende Nukleinsäure
DE60043258D1 (de) Menschliches suppressor von fused

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties